Slide 1: FY17 results
FY17 results Ian Kadish (MD & CEO) Anne Lockwood (Interim-CFO) 24 August 2017
Slide 2: Profit & loss
Profit & loss Change Change $ millions, June FY17 FY16 ($m) (%) Total revenue 179.7 167.8 11.9 7.1% NPAT 15.5 11.4 4.1 35.9% Add back: Amortisation 0.4 0.4 0.0 0.0% NPATA 15.9 11.8 4.1 34.7% One off transactions net of tax Transaction costs (5.2) Impairment of asset and restructuring provision (0.8)
Slide 3: Cashflow
Cashflow $ millions, June year end FY17 FY16 Operating cashflows 22.7 24.1 Investing cashflows (14.7) (16.7) Financing cashflows (7.4) 6.6 • FY17 investing cashflows include SWMRI/WDR acquisition • FY17 financing cashflows include $10.2m of dividend payments • FY16 financing cashflows include IPO pr
Slide 4: Balance sheet
Actual Actual Balance sheet $ millions 30-Jun-17 30-Jun-16 Cash and cash Conservative gearing equivalents 24.2 23.6 Trade and other • Property, plant and equipment increased receivables 5.1 5.5 by $3.9m due to acquisition of Other current assets 3.9 2.9 SWMRI/WDR, ongoing investment in Total current
Slide 5: Industry volume growth is still in recovery
Industry volume growth is still in recovery 14% 12 month rolling growth rate by services 12 month rolling growth rate by benefits Average 5.8% Average 7.6% 12% 10% 8% 6% 4% 2% Apr-17 Feb-12 Apr-12 Feb-13 Apr-13 Feb-14 Apr-14 Feb-15 Apr-15 Feb-16 Apr-16 Feb-17 Oct-12 Oct-13 Oct-14 Oct-15 Oct-16 Dec-1
Slide 6: FY17 operations
FY17 operations • Acquired and integrated SWMRI/WDR • Expanded capacity in Toowoomba, Sunbury and Geelong supporting full year growth • Signed five, 5 year contracts with the West Australian Country Health Service relating to the provision of reporting contracts in remote regions, two of which were
Slide 7: Capex
Capex ($M) FY16 FY17 FY18 Maintenance 9.5 11.1 11.0 Growth 7.9 2.3 8.0 Depreciation 8.7 9.8 11.0 • $13.4m capex (net of acquisitions) (FY16: $17.5m) – Maintenance capex of $11.1m as planned • Medical equipment and fit out of hospitals/practices • IT systems – Growth capex of $2.3m • Mobile MRI • Por
Slide 8: Focused strategy, disciplined execution into FY18
Focused strategy, disciplined execution into FY18 Strategy 1 Grow existing business and contain costs 2 Strategic acquisitions Develop dedicated Increase Select Bolt- Drivers of Flex staff to sub- capacity on Disciplined execution strategy demand speciality utilisation Acquisitions centres Geographi
Slide 9: Outlook
Outlook FY18 focus 1. Improve utilisation of existing capacity and infrastructure 2. Contain costs so revenue growth delivers improved returns 3. Develop dedicated sub-speciality centres such as the recently opened Spine Clinic 4. Execute value-accretive acquisitions Improved Regulatory Environment
Slide 10: Questions
fig integral qi DIAGNOSTICS fis
Slide 11: Disclaimer
Disclaimer Some of the information contained in this presentation contains “forward-looking statements” which may not directly or exclusively relate to historical facts. These forward-looking statements reflect Integral Diagnostics Limited (IDX) current intentions, plans, expectations, assumptions a
Slide 12: Contact us
Contact us Investors & Media Dr Ian Kadish, CEO P: +61 3 5339 0704 E: kadishi@integraldiagnostics.com.au